New publication on Autophagy

7 Jun 2024 | Discover home page, Discover SigDyn

New publication on Autophagy Liver cancer chloroquine cholangio carcinoma therapy microbial metabolite cell death butyrate, oxidative stress Hala Shalhoub – Equipe SigDyn – Integrated cellular signalling and PI3K isoforms Our cells can eat itself through a...

Focus research 2022 SigDyn team

30 Sep 2023 | Discover SigDyn

Focus research 2022 SigDyn team Cross-regulation between PI3Ks Can they be used to better prevent tumor progression?PI3Ks are a family of three classes of enzymes essential to cell life and which are frequently deregulated in cancer. The dependence of tumors on...

Cancer under pressure: which signals are activated?

30 Jun 2023 | Discover home page, Discover SigDyn

Cancer under pressure: which signals are activated? mechanical forces, cancer, mechanosensing,  compression, confinement,  targeted therapies,  cell signaling. Julie Guillermet-Guibert Team SigDyn Integrated cellular signalling and PI3K isoforms In living organisms,...

How to target PI3Ks 3 classes in cancer?

17 Feb 2023 | Discover home page, Discover SigDyn

How to target PI3Ks 3 classes in cancer? PI3K, cell signaling, Combi/hydrides-molecules, combination therapeutics, Cancer, Benoît Thibault, équipe SigDyn – Signalisation cellulaire intégrée et isoformes de PI3K PI3Ks are a family of 3 classes of enzymes that are...

The cell signalling enzymes PI3Kalpha and PI3Kβ play major roles in the body.

17 Dec 2021 | Discover home page, Discover SigDyn

The cell signalling enzymes PI3Kalpha and PI3Kβ play major roles in the body. Cell signalling Cancer Oncogenic signalling tumour suppressors PI3K/AKT/mTOR Dr Julie Guillermet-Guibert – CRCT team : SigDYN : Integration of cellular signals & PI3K class I, II,...

The PACMINE project is selected for the Toulouse Cancer Health Foundation’s call for funds

17 Dec 2021 | Discover home page, Discover SigDyn

The PACMINE project is selected for the Toulouse Cancer Health Foundation’s call for funds The PACMINE project, led by Julie Guillermet-Guibert, Research Officer at the CRCT (Toulouse Cancer Research Centre), and Elisa Boutet-Robinet, Researcher at Toxalim and...